Abstract | OBJECTIVE: In the treatment of endometrial stromal sarcoma, it is still not clear whether adjuvant radiation therapy improves the outcome. We wish to summarize the experiences we gathered from treating 15 patients over a period of 18 years, and to compare these to results from literature. PATIENTS AND METHODS: RESULTS: Follow up ranged from 23 to 170 months (mean: 80 mths). 10 patients (67%) are still alive without tumor, and 5 patients have died. Of these, one died due to intercurrent disease, one due to breast-cancer, and 3 due to endometrial stromal sarcoma, presenting distant metastases within one year after therapy. Only one patient presented with an additional local recurrence. The overall actuarial survival and the disease specific survival rate was 72% and 79% respectively after 5 years, and 60% and 79% after 10 years. The overall local control rate was 93% after 5 years. There were no severe acute side effects and no late side effects. CONCLUSION:
|
Authors | Hajo Dirk Weitmann, Herwig Kucera, Tomas-Hendrik Knocke, Richard Pötter |
Journal | Wiener klinische Wochenschrift
(Wien Klin Wochenschr)
Vol. 114
Issue 1-2
Pg. 44-9
(Jan 15 2002)
ISSN: 0043-5325 [Print] Austria |
PMID | 12407935
(Publication Type: Journal Article)
|
Topics |
- Aged
- Austria
- Brachytherapy
- Combined Modality Therapy
- Endometrial Neoplasms
(mortality, pathology, radiotherapy, surgery)
- Female
- Follow-Up Studies
- Humans
- Hysterectomy
- Middle Aged
- Neoplasm Staging
- Ovariectomy
- Radiotherapy Dosage
- Radiotherapy, Adjuvant
- Sarcoma, Endometrial Stromal
(mortality, pathology, radiotherapy, surgery)
- Survival Rate
|